CN111249331A - Vitamin medicine composition and preparation method and application thereof - Google Patents
Vitamin medicine composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN111249331A CN111249331A CN202010197937.8A CN202010197937A CN111249331A CN 111249331 A CN111249331 A CN 111249331A CN 202010197937 A CN202010197937 A CN 202010197937A CN 111249331 A CN111249331 A CN 111249331A
- Authority
- CN
- China
- Prior art keywords
- filtrate
- vitamin
- hyssop
- primary
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of preparation of a vitamin medicine composition, in particular to a vitamin medicine composition and a preparation method and application thereof. The vitamin composition can effectively reduce the nerve function loss score and the cerebral infarction area of a cerebral ischemia reperfusion rat, can play a role in relieving oxidative stress injury and inhibiting inflammatory reaction, can relieve pathological injury of nerve cells, has a nerve protection effect, relieves cerebral ischemia reperfusion injury, and has a good curative effect on cerebral ischemic stroke diseases.
Description
Technical Field
The invention relates to the technical field of preparation of a vitamin medicine composition, and relates to a vitamin medicine composition and a preparation method and application thereof.
Background
Cerebral ischemic stroke disease belongs to the category of stroke in traditional Chinese medicine, and is one of the main reasons for causing disability and killing millions of people in the world due to high morbidity, recurrence rate and mortality. Research reports that the morbidity and mortality of ischemic stroke in China are higher than the world level and gradually increase year by year, and the proportion of cerebrovascular diseases accounts for more than 20% of the death rate of diseases of residents in China in 2017. at present, the recovery of blood perfusion of tissues in an ischemic area through thrombolytic therapy is the most effective treatment method, but has higher complications such as bleeding, so that the understanding of the specific morbidity process of ischemic stroke provides a basis for finding new and more effective therapies and medicines, and meanwhile, how to relieve cerebral ischemia reperfusion injury is one of the keys for improving the curative effect of ischemic stroke.
Uygur medicine is an important part of traditional Chinese medicine in China and plays a key role in preventing and treating diseases, traditional Chinese medicine has the effects of antagonizing cerebral ischemia reperfusion inflammation reaction, relieving oxidative stress injury and the like, and traditional Chinese medicine preparation is a hotspot of neuroprotection research of ischemic stroke diseases at present due to higher safety and higher nerve function protection effect. All-grass of Thymus
(Hyssopus cuspidus Boriss.) and Dracocephalum moldovlia L are used as Uygur medicinal materials for treating abnormal mucus diseases, airway inflammation diseases and cardiovascular diseases, and have antioxidant, antiinflammatory, antithrombotic and vasodilating effects. The hyssop and the moldavica dragonhead have higher safety through long-term clinical practice of Uygur medicine. At present, the medicine prepared by combining the hyssop and the moldavica dragonhead for treating cerebral ischemic stroke diseases is not reported.
Disclosure of Invention
The invention provides a Uighur medicine composition, a preparation method and application thereof, overcomes the defects of the prior art, and can effectively solve the problem of complications such as bleeding caused by thrombolytic drugs for treating cerebral ischemic stroke diseases in the prior art thrombolytic therapy.
One of the technical schemes of the invention is realized by the following measures: a vitamin medicine composition comprises, by weight, 10-50 parts of hyssop and 10-50 parts of moldavica dragonhead, and is obtained by the following method: firstly, mixing required amount of hyssop and moldavica dragonhead, adding water, refluxing, extracting and filtering to obtain primary filtrate and primary dregs respectively; secondly, adding water into the primary medicine residues for reflux extraction and filtering to respectively obtain secondary filtrate and secondary medicine residues; thirdly, adding ethanol into the secondary decoction dregs, standing, recovering the ethanol in the secondary decoction dregs, and filtering to obtain a third filtrate; and fourthly, combining the primary filtrate, the secondary filtrate and the tertiary filtrate to obtain a mixed filtrate, and concentrating the mixed filtrate to obtain the vitamin medicine composition.
The following is a further optimization or/and improvement of one of the above-mentioned technical solutions of the invention:
in the first step, water with the weight 8-12 times of the total weight of the hyssop and the moldavica dragonhead is added for reflux extraction for 1.8-2.2 h.
In the second step, water with the weight 6-10 times of the total weight of the hyssop and the moldavica dragonhead is added for reflux extraction for 0.8-1.2 h.
In the third step, ethanol which is 4 times of the total weight of the hyssop and the moldavica dragonhead is added, and the standing time is 10-14 h, wherein the mass percent of the ethanol is 70-90%.
The second technical scheme of the invention is realized by the following measures: the preparation method of the vitamin medicine composition comprises the following steps: firstly, mixing required amount of hyssop and moldavica dragonhead, adding water, refluxing, extracting and filtering to obtain primary filtrate and primary dregs respectively; secondly, adding water into the primary medicine residues for reflux extraction and filtering to respectively obtain secondary filtrate and secondary medicine residues;
thirdly, adding ethanol into the secondary decoction dregs, standing, recovering the ethanol in the secondary decoction dregs, and filtering to obtain a third filtrate; and fourthly, combining the primary filtrate, the secondary filtrate and the tertiary filtrate to obtain a mixed filtrate, and concentrating the mixed filtrate to obtain the vitamin medicine composition.
The following is further optimization or/and improvement of the second technical scheme of the invention:
in the first step, water with the weight 8-12 times of the total weight of the hyssop and the moldavica dragonhead is added for reflux extraction for 1.8-2.2 h.
In the second step, water with the weight 6-10 times of the total weight of the hyssop and the moldavica dragonhead is added for reflux extraction for 0.8-1.2 h.
In the third step, ethanol which is 4 times of the total weight of the hyssop and the moldavica dragonhead is added, and the standing time is 10-14 h, wherein the mass percent of the ethanol is 70-90%.
The third technical scheme of the invention is realized by the following measures: an application of Uighur medicine composition in preparing the medicines for treating ischemic cerebral apoplexy is disclosed.
The vitamin composition can effectively reduce the nerve function loss score and the cerebral infarction area of a rat subjected to cerebral ischemia reperfusion, can play a role in relieving oxidative stress injury and inhibiting inflammatory reaction, can relieve the pathological injury of nerve cells, has a neuroprotective effect, relieves the cerebral ischemia reperfusion injury, and has a good curative effect on cerebral ischemic stroke.
Drawings
FIG. 1 is a graph of infarct size of brain tissue of rats subjected to cerebral ischemia-reperfusion and stained with TTC.
FIG. 2 is a diagram of pathological changes in hippocampus of cerebral ischemia-reperfusion rat brain tissue.
Detailed Description
The present invention is not limited by the following examples, and specific embodiments may be determined according to the technical solutions and practical situations of the present invention. The various chemical reagents and chemical articles mentioned in the invention are all the chemical reagents and chemical articles which are well known and commonly used in the prior art, unless otherwise specified; the percentages in the invention are mass percentages unless otherwise specified; the solution in the present invention is an aqueous solution in which the solvent is water, for example, a hydrochloric acid solution is an aqueous hydrochloric acid solution, unless otherwise specified; the normal temperature and room temperature in the present invention generally mean a temperature of 15 ℃ to 25 ℃, and are generally defined as 25 ℃.
The invention is further described below with reference to the following examples:
example 1: the vitamin medicine composition comprises the following raw materials, by weight, 10-50 parts of hyssop and 10-50 parts of moldavica dragonhead, and is obtained by the following method: firstly, mixing required amount of hyssop and moldavica dragonhead, adding water, refluxing, extracting and filtering to obtain primary filtrate and primary dregs respectively; secondly, adding water into the primary medicine residues for reflux extraction and filtering to respectively obtain secondary filtrate and secondary medicine residues; thirdly, adding ethanol into the secondary decoction dregs, standing, recovering the ethanol in the secondary decoction dregs, and filtering to obtain a third filtrate; and fourthly, combining the primary filtrate, the secondary filtrate and the tertiary filtrate to obtain a mixed filtrate, and concentrating the mixed filtrate to obtain the vitamin medicine composition.
Example 2: the vitamin medicine composition comprises the following raw materials of 10 parts or 50 parts of hyssop and 10 parts or 50 parts of moldavica dragonhead according to parts by weight, and is obtained by the following method: firstly, mixing required amount of hyssop and moldavica dragonhead, adding water, refluxing, extracting and filtering to obtain primary filtrate and primary dregs respectively; secondly, adding water into the primary medicine residues for reflux extraction and filtering to respectively obtain secondary filtrate and secondary medicine residues; thirdly, adding ethanol into the secondary decoction dregs, standing, recovering the ethanol in the secondary decoction dregs, and filtering to obtain a third filtrate; and fourthly, combining the primary filtrate, the secondary filtrate and the tertiary filtrate to obtain a mixed filtrate, and concentrating the mixed filtrate to obtain the vitamin medicine composition.
Example 3: as optimization of the above example, in the first step, 8 to 12 times of water of the total weight of the hyssop and the moldavica dragonhead is added for reflux extraction for 1.8 to 2.2 hours.
Example 4: as an optimization of the above example, in the second step, water in an amount of 6 to 10 times of the total weight of the hyssop and the moldavica dragonhead is added for reflux extraction for 0.8 to 1.2 hours.
Example 5: as the optimization of the above embodiment, in the third step, 4 times of ethanol of the total weight of the hyssop and the moldavica dragonhead is added, and the standing time is 10h to 14h, wherein the mass percent of the ethanol is 70 percent to 90 percent.
Example 6: the vitamin medicine composition comprises the following raw materials of 10 parts of hyssop and 10 parts of moldavica dragonhead by weight, and is obtained by the following method: firstly, mixing 10 parts of hyssop and 10 parts of moldavica dragonhead, adding water with the weight being 8 times of the total weight of the hyssop and the moldavica dragonhead, refluxing and extracting for 1.8 hours, and filtering to obtain primary filtrate and primary medicine residue respectively; secondly, adding water of which the weight is 6 times of the total weight of the hyssop and the vanilla into the primary medicine residue, performing reflux extraction for 0.8h, and filtering to obtain secondary filtrate and secondary medicine residue respectively; thirdly, adding ethanol which is 4 times of the total weight of the hyssop and the vanilla into the secondary medicine dregs, standing for 10 hours, recovering the ethanol in the secondary medicine dregs, and filtering to obtain third filtrate, wherein the mass percent of the ethanol is 70%; and fourthly, combining the primary filtrate, the secondary filtrate and the tertiary filtrate to obtain a mixed filtrate, and concentrating the mixed filtrate to obtain the vitamin medicine composition.
Example 7: the vitamin medicine composition comprises 50 parts of hyssop and 50 parts of moldavica dragonhead according to parts by weight, and is obtained by the following method: firstly, mixing 50 parts of hyssop and 50 parts of moldavica dragonhead, adding water with the weight being 12 times of the total weight of the hyssop and the moldavica dragonhead, refluxing and extracting for 2.2 hours, and filtering to respectively obtain primary filtrate and primary medicine residues; secondly, adding water which is 10 times of the total weight of the hyssop and the vanilla to the primary medicine residue, refluxing and extracting for 1.2h, and filtering to obtain secondary filtrate and secondary medicine residue respectively; thirdly, adding ethanol which is 4 times of the total weight of the hyssop and the vanilla into the secondary medicine residue, standing for 14 hours, recovering the ethanol in the secondary medicine residue, and filtering to obtain third filtrate, wherein the mass percent of the ethanol is 80%; and fourthly, combining the primary filtrate, the secondary filtrate and the tertiary filtrate to obtain a mixed filtrate, and concentrating the mixed filtrate to obtain the vitamin medicine composition.
Example 8: the vitamin medicine composition comprises 25 parts of hyssop and 25 parts of moldavica dragonhead according to parts by weight, and is obtained by the following method: firstly, mixing 25 parts of hyssop and 25 parts of moldavica dragonhead, adding water with the weight being 10 times of the total weight of the hyssop and the moldavica dragonhead, refluxing and extracting for 2.0h, and filtering to respectively obtain primary filtrate and primary medicine residues; secondly, adding water which is 8 times of the total weight of the hyssop and the vanilla to the primary medicine residue, refluxing and extracting for 1.0 hour, and filtering to obtain secondary filtrate and secondary medicine residue respectively; thirdly, adding ethanol which is 4 times of the total weight of the hyssop and the vanilla into the secondary medicine dregs, standing for 12 hours, recovering the ethanol in the secondary medicine dregs, and filtering to obtain third filtrate, wherein the mass percent of the ethanol is 90%; and fourthly, combining the primary filtrate, the secondary filtrate and the tertiary filtrate to obtain a mixed filtrate, and concentrating the mixed filtrate to obtain the vitamin medicine composition.
The following is a study of the therapeutic effect of the vitamin composition prepared in example 8 of the present invention on cerebral ischemia-reperfusion injury in rats.
Pharmacological test
1. Establishment of cerebral ischemia reperfusion model rat
Test animals: adopting healthy and clean male SD rats, and feeding the rats in the laboratory animal center of Shanghai medical institute of Compound denier university under the following feeding conditions: clean grade, fixed illumination time and free intake of water and food.
Grouping and administration: the rats are randomly grouped into 18 rats in each group, namely a control group (a sham operation group), a model group and an administration group, wherein the administration group is prepared by adding distilled water into the vitamin medicine composition prepared in the embodiment 8 of the invention to dilute the composition to the concentration of 2g/ml, the administration dose is 4g/kg, and the administration mode is intragastric administration for 1 time per day; the control group and the model group were both administered with an equal amount of physiological saline instead, and 7 days after each administration, a cerebral ischemia-reperfusion model was prepared and examined 24 hours after ischemia-reperfusion.
The method for establishing the cerebral ischemia reperfusion model comprises the following steps: after 1 hour of administration on the seventh day, rats were anesthetized by intraperitoneal injection of 10% chloral hydrate, fixed on an operating table in a supine position after anesthesia, trimmed to the left in the center of the neck, the right common carotid artery and the right external jugular vein were exposed and separated, cannulated in the reverse direction from the distal end of the right common carotid artery and ligated to the proximal end, the tampon was inserted into the internal carotid artery approximately 18.0mm ± 2.0mm through the external carotid artery and reached the middle cerebral artery and blocked, after 30 minutes of ischemia, the tampon was withdrawn, sterilized with alcohol after confirming no bleeding, and then, the skin was sutured with penicillin powder. In the control group, the plug was inserted into the carotid artery but not deep into the middle cerebral artery, and the rest of the procedure was the same.
The cord lock may be a 2838-A4 cord lock available from Beijing Western Biotechnology, Inc.
2. The influence of the vitamin composition on the death rate and the neurological function loss score of the cerebral ischemia-reperfusion rat is examined
The test method comprises the following steps: rats 24h post-operative reperfusion were neuro-behavioural scored (Longa scoring method), scoring criteria: score 0 no obvious damage, normal activity; 1 is divided into that the right forelimb can not be completely straightened; 2, turning to the right side; 3, inclining towards the right; 4, the patient cannot walk spontaneously and loses consciousness; and 5, death.
And (3) test results: comparison of mortality and neurological loss scores in groups of rats
As shown in table 1, as can be seen from table 1, the loss of nerve function score of the model group rats was significantly increased compared to the control group rats; compared with the rats in the model group, the rats in the administration group have the tendency of obviously reducing the nerve function loss score, which shows that the vitamin composition can improve the nerve function of the rats subjected to cerebral ischemia reperfusion.
3. The influence of the vitamin composition on the cerebral infarction area of the cerebral ischemia reperfusion rat is investigated
The test method comprises the following steps: the rat which is perfused for 24 hours after operation is anesthetized by 10 percent chloral hydrate intraperitoneal injection, the head is broken after anesthesia to take the brain, the brain tissue is rapidly stripped and put into a low-temperature refrigerator at the temperature of 20 ℃ below zero for freezing for 15min, the parts of an olfactory bulb, the cerebellum and the lower brain stem are removed, the brain tissue is continuously cut into coronal slices with the thickness of 2mm, the coronal slices are placed into a phosphate buffer solution with the temperature of 37 ℃ and the temperature of 2 percent and soaked in the dark for 15min, the coronal slices are turned over for 1 time during the process to be beneficial to fully dyeing the two sides of the brain tissue slices, the coronal slices are taken out and placed into a phosphate buffer solution with the concentration of 4 percent paraformaldehyde for soaking for 30min after dyeing, the coronal slices are stored and photographed, the normal brain tissue is dyed into red, the infarct.
And (3) test results: comparison of cerebral infarct size in rats of each group
As shown in the figure1 and table 2, wherein a in fig. 1 is a control group, b is a model group, and c is an administration group; in Table 1, P represents the comparison of the model group with the control group<0.001；△Denotes comparison of the administration group with the model group, P<0.05, as can be seen from fig. 1 and table 2, compared with the control group rat, the cerebral infarction area of the model group rat is obviously increased, and compared with the model group rat, the cerebral infarction area of the administration group rat is obviously reduced, which indicates that the vitamin composition can effectively reduce the cerebral infarction area of the cerebral ischemia reperfusion rat.
4. The influence of the vitamin composition on the content of malondialdehyde MDA and superoxide dismutase SOD in the brain tissue of a rat subjected to cerebral ischemia reperfusion is examined
The test method comprises the following steps: the rats which are 24h of postoperative reperfusion are anesthetized by 10% chloral hydrate intraperitoneal injection, the brains are taken out after anesthesia, the brain tissues are rapidly stripped, the left brain tissue (side of the plug wire bolt) is cut from the sagittal shape, and after the brain tissues are washed by normal saline, the ratio of the normal saline (ml) to the normal saline (ml) is determined: brain tissue (g) ═ 9: 1, adding pre-cooled normal saline, crushing to obtain 10% brain homogenate, centrifuging the brain homogenate for 10min at the temperature of 4 ℃ and the rotating speed of 3000r/min, and taking supernatant to measure the contents of malondialdehyde MDA and superoxide dismutase SOD in brain tissues, wherein the content measurement of the malondialdehyde MDA and the superoxide dismutase SOD is carried out according to the kit instructions, and the kit can be provided by bioengineering research institute built from Nanjing.
And (3) test results: comparison of malonaldehyde MDA and superoxide dismutase SOD content in rat brain tissue of each group
As shown in table 2, in which,***representing the comparison of the model group with the control group, P<0.001；△Denotes comparison of the administration group with the model group, P<0.05，△△Denotes comparison of the administration group with the model group, P<0.01, as can be seen from table 2, compared with the control group rats, the Malondialdehyde (MDA) content in the brain tissue is obviously increased and the superoxide dismutase (SOD) content is obviously reduced after the model group rats are subjected to cerebral tissue ischemia reperfusion for 24 hours; the brain tissue of the rats of the administration group had malondialdehyde MDA content in comparison with that of the rats of the model groupObviously reduces the content of superoxide dismutase SOD and obviously increases the content of superoxide dismutase SOD, which indicates that the vitamin medicine composition can play a role in relieving oxidative stress injury.
5. The influence of the vitamin composition on the pathological change of the cerebral ischemia reperfusion rat brain tissue hippocampus is investigated
The test method comprises the following steps: the rats which are 24h of post-operation reperfusion are anesthetized by 10 percent chloral hydrate intraperitoneal injection, the brains are taken out after anesthesia, fixed in 4 percent paraformaldehyde, and then are subjected to perfusion-shaped section of brain tissues, embedded by conventional paraffin and HE staining so as to observe pathological changes of hippocampus and cortex.
And (3) test results: as shown in fig. 2, in which a is a control group, b is a model group, and c is an administration group, it can be seen from fig. 2 that the control group shows no edema in the hippocampus, the nerve cells are substantially normal, and the solid shrinkage of individual neurons (as shown by arrow 1) can be seen; the model group shows that the meninges of the hippocampus are highly edematous and have blood vessel expansion, the adjacent hippocampus can be seen that individual neuron is fixed (as shown by an arrow 1), the staining is deepened, local nerve fibers are vacuolated (as shown by an arrow 2), and the infarct area accounts for more than 2/3 of the hippocampus tissues; the administration group shows that the hippocampus has edema, and the area of neuron contraction infarction of the visible part of the adjacent hippocampus accounts for more than 1/3 of the hippocampus tissue, which shows that the vitamin composition has the neuroprotective effect and can alleviate the pathological damage of nerve cells caused by ischemia-reperfusion rats.
6. The influence of the vitamin composition on the contents of inflammatory factors IL-6 and TNF-a in the brain tissue of a rat subjected to cerebral ischemia reperfusion is investigated
The test method comprises the following steps: in the same manner as in test 4, the supernatant was collected and the contents of the inflammatory factors IL-6 and TNF-a in the brain tissue were measured, wherein the contents of the inflammatory factors IL-6 and TNF-a were measured according to the instructions of the kit, and the kit was supplied by RayBiotech, USA.
And (3) test results: comparison of the content of inflammatory factors IL-6 and TNF-a in brain tissue of rats in each group
As shown in table 3, in which,**representing the comparison of the model group with the control group, P<0.01，***To representComparison of model groups with control groups, P<0.001；△Denotes comparison of the administration group with the model group, P<0.05, and as can be seen from Table 3, compared with the control group of rats, the contents of inflammatory factors IL-6 and TNF-a in the brain tissues of the model group of rats are obviously increased; compared with a model group of rats, the content of inflammatory factors IL-6 and TNF-a in brain tissues of the rats in the administration group is obviously reduced, which shows that the vitamin composition has an inhibiting effect on the inflammatory reaction of the rats subjected to cerebral ischemia reperfusion.
In conclusion, the vitamin composition can effectively reduce the nerve function loss score and the cerebral infarction area of a cerebral ischemia reperfusion rat, can play a role in relieving oxidative stress injury and inhibiting inflammatory reaction, can relieve the pathological injury of nerve cells, has a neuroprotective effect, relieves cerebral ischemia reperfusion injury, and has a good curative effect on cerebral ischemic stroke.
The technical characteristics form an embodiment of the invention, which has strong adaptability and implementation effect, and unnecessary technical characteristics can be increased or decreased according to actual needs to meet the requirements of different situations.
TABLE 1
| Group of | Survival number (only) | Mortality (%) | Neurological loss score |
| Control group | 18 | 0 | 0.00±0.52 |
| Model set | 12 | 33.3 | 3.45±0.52*** |
| Administration set | 14 | 22.2 | 2.83±0.57△ |
TABLE 2
TABLE 3
| Group of | IL-6(pg/ml) | TNF-a(pg/ml) |
| Control group | 22.9±6.62 | 40.4±11.2 |
| Model set | 56.5±15.1** | 74.9±15.2*** |
| Administration set | 31.9±7.77 | 52.4±8.79△ |
Claims (9)
1. The vitamin medicine composition is characterized by comprising the following raw materials in parts by weight of 10-50 parts of hyssop and 10-50 parts of moldavica dragonhead, and is obtained by the following method: firstly, mixing required amount of hyssop and moldavica dragonhead, adding water, refluxing, extracting and filtering to obtain primary filtrate and primary dregs respectively; secondly, adding water into the primary medicine residues for reflux extraction and filtering to respectively obtain secondary filtrate and secondary medicine residues; thirdly, adding ethanol into the secondary decoction dregs, standing, recovering the ethanol in the secondary decoction dregs, and filtering to obtain a third filtrate; and fourthly, combining the primary filtrate, the secondary filtrate and the tertiary filtrate to obtain a mixed filtrate, and concentrating the mixed filtrate to obtain the vitamin medicine composition.
2. The vitamin composition according to claim 1, wherein in the first step, water is added in an amount of 8 to 12 times the total weight of the hyssop and the moldavica dragonhead for reflux extraction for 1.8 to 2.2 hours.
3. The vitamin composition according to claim 1 or 2, wherein in the second step, water is added in an amount of 6 to 10 times of the total weight of hyssop and vanilla to reflux-extract for 0.8 to 1.2 hours.
4. The vitamin composition according to claim 1, 2 or 3, wherein in the third step, ethanol is added in an amount which is 4 times of the total weight of the hyssop and the moldavica dragonhead, and the standing time is 10h to 14h, wherein the mass percentage of the ethanol is 70% to 90%.
5. The preparation method of the vitamin medicine composition is characterized by comprising the following steps: firstly, mixing required amount of hyssop and moldavica dragonhead, adding water, refluxing, extracting and filtering to obtain primary filtrate and primary dregs respectively; secondly, adding water into the primary medicine residues for reflux extraction and filtering to respectively obtain secondary filtrate and secondary medicine residues; thirdly, adding ethanol into the secondary decoction dregs, standing, recovering the ethanol in the secondary decoction dregs, and filtering to obtain a third filtrate; and fourthly, combining the primary filtrate, the secondary filtrate and the tertiary filtrate to obtain a mixed filtrate, and concentrating the mixed filtrate to obtain the vitamin medicine composition.
6. The method for preparing a vitamin composition according to claim 5, wherein in the first step, water is added in an amount of 8 to 12 times the total weight of hyssop and vanilla to reflux for 1.8 to 2.2 hours.
7. The method for preparing a vitamin composition according to claim 5 or 6, wherein in the second step, water is added in an amount of 6 to 10 times of the total weight of hyssop and vanilla to reflux the mixture for 0.8 to 1.2 hours.
8. The preparation method of the vitamin composition according to claim 5, 6 or 7, wherein in the third step, 4 times of the total weight of the hyssop and the vanilla are added, and the standing time is 10h to 14h, wherein the mass percent of the ethanol is 70% to 90%.
9. Use of the Uighur composition according to claims 1 to 4 for the preparation of a medicament for the treatment of ischemic stroke diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010197937.8A CN111249331A (en) | 2020-03-19 | 2020-03-19 | Vitamin medicine composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010197937.8A CN111249331A (en) | 2020-03-19 | 2020-03-19 | Vitamin medicine composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111249331A true CN111249331A (en) | 2020-06-09 |
Family
ID=70944296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010197937.8A Pending CN111249331A (en) | 2020-03-19 | 2020-03-19 | Vitamin medicine composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111249331A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537039A (en) * | 2009-04-24 | 2009-09-23 | 山东大学 | Moldavica dragonhead general flavone extract as well as preparation method and application thereof |
| CN102138967A (en) * | 2010-01-29 | 2011-08-03 | 孙雅煊 | Application of dracocephalum moldavica L. general flavone in preparing medicament for preventing and treating cerebrovascular disease |
| CN102697769A (en) * | 2012-06-11 | 2012-10-03 | 新疆德泓生物科技有限公司 | Use of flavonoid compound originated from Dracocephalum moldavica in protecting myocardial ischemia reperfusion injury |
| CN110522798A (en) * | 2019-09-24 | 2019-12-03 | 新疆华春生物药业股份有限公司 | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease |
-
2020
- 2020-03-19 CN CN202010197937.8A patent/CN111249331A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101537039A (en) * | 2009-04-24 | 2009-09-23 | 山东大学 | Moldavica dragonhead general flavone extract as well as preparation method and application thereof |
| CN102138967A (en) * | 2010-01-29 | 2011-08-03 | 孙雅煊 | Application of dracocephalum moldavica L. general flavone in preparing medicament for preventing and treating cerebrovascular disease |
| CN102697769A (en) * | 2012-06-11 | 2012-10-03 | 新疆德泓生物科技有限公司 | Use of flavonoid compound originated from Dracocephalum moldavica in protecting myocardial ischemia reperfusion injury |
| CN110522798A (en) * | 2019-09-24 | 2019-12-03 | 新疆华春生物药业股份有限公司 | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease |
Non-Patent Citations (4)
| Title |
|---|
| LU ZHAO，等: "HPLC-DAD analysis of Hyssopus Cuspidatus Boriss extract and mensuration of its antioxygenation property", 《BMC COMPLEMENTARY MEDICINE AND THERAPIES》 * |
| 孙雅煊,等: "香青兰总黄酮对短暂性脑缺血诱导的", 《生物物理学报》 * |
| 张丽萍，等: "脑缺血再灌注损伤对血清及脑SOD、MDA、NO、NOS的影响", 《齐鲁医学检验》 * |
| 王兆松，等: "神香草野生种与引进种的精油成分的异同", 《新疆农垦科技》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6063383A (en) | Pharmaceutical suppository composites for fever and influenza and method of producing the composites | |
| KR101549944B1 (en) | Composition for treating and preventing overavtive bladder and cystitis | |
| JP2014509609A (en) | Composition for treatment or prevention of degenerative neurological disease containing herbal extract | |
| CN104815192A (en) | Pharmaceutical composition for treating hypertension and application of pharmaceutical composition | |
| CN107753535B (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases and application thereof | |
| KR101600751B1 (en) | Method of preparing oriental medicine composition containing extract of deer antlers for treating infertility in women | |
| CN111249331A (en) | Vitamin medicine composition and preparation method and application thereof | |
| WO2008010663A1 (en) | Sophoricoside-containing composition for reducing body-weight or body-fat | |
| KR100991399B1 (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata, Centella asiatica, Plantago asiatica, Ulmus davidana var. Japonica and Morus alba L. as an active ingredient | |
| CN113244303B (en) | A pharmaceutical composition for treating primary headache, and its preparation method | |
| CN106074673B (en) | Application of Dai medicine desmodium styracifolium in preparation of medicine or health food for treating male erectile dysfunction | |
| CN107854505B (en) | New use of combination of pseudo-ginseng and aspirin | |
| CN110507707A (en) | A kind of Chinese medicine composition and preparation method thereof for treating type II diabetes | |
| CN115444874B (en) | Pseudo-ginseng traditional Chinese medicine ointment for activating blood circulation to dissipate blood stasis and preparation method thereof | |
| CN108114029A (en) | A kind of active Chinese drug component compositions, its preparation method and its application | |
| CN110151922B (en) | Traditional Chinese medicine composition for treating angina pectoris complicated with hypertension and preparation method thereof | |
| JP4636475B2 (en) | Antidiabetic | |
| CN112755058B (en) | Application of devilpepper ethanol extract in preparation of medicine for relaxing and pre-contracting tracheal smooth muscle | |
| CN111000886B (en) | Pharmaceutical composition for treating cerebral arterial thrombosis and application thereof | |
| CN108743866B (en) | Hongbao heart-soothing oral liquid and application thereof in preparation of cardiovascular disease drugs | |
| CN108186737B (en) | External drop for treating paronychia and preparation method thereof | |
| CN108785330B (en) | Application of periplaneta americana extract in preparation of medicine for treating wound healing | |
| CN116059287A (en) | Plant fermentation liquid for regulating endocrine dyscrasia and maintaining uterus, and preparation method and application thereof | |
| CN117860819A (en) | Traditional Chinese medicine composition for treating systemic sclerosis and preparation method thereof | |
| CN114073738A (en) | Traditional Chinese medicine composition and extraction process and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200609 |